CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma - Kumai, Takumi; Nagato, Toshihiro; Kobayashi, Hiroya; Komabayashi, Yuki; Ueda, Seigo; Kishibe, Kan; Ohkuri, Takayuki; Takahara, Miki; Celis, Esteban; Harabuchi, Yasuaki (Cancer Immunology, Immunotherapy, 2015)
Keywords: Antibodies; Cancer; Cancer Research; Chemokine CCL17 - immunology; Chemokine CCL22 - immunology; Chemokines; Cytotoxicity; Epstein-Barr virus; Humans; Immunology; Immunotherapy - methods; Leukemia; Ligands; Lymphoma; Lymphoma, Extranodal NK-T-Cell - immunology; Lymphoma, Extranodal NK-T-Cell - therapy; Lymphoma, T-Cell; Medicine; Medicine & Public Health; Molecular Targeted Therapy; Oncology; Original Article; Otolaryngology; Proteins; Receptors, CCR4 - immunology; Signal Transduction; Thymus gland; United States--US; Japan; Chemokine; CCL22; CCR4; CCL17; Nasal NK/T-cell lymphoma